Medicamen Biotech Limited (MEDICAMEQ) AI Stock Analysis

Medicamen Biotech Limited

(NSE:MEDICAMEQ)

Select Model

Rating:60Neutral

Price Target:INR 268.00▲(4.89% Upside)

Action:reiterated

Date:09/17/26

The score is held back primarily by weak cash-flow quality (multi-year negative operating/free cash flow) and a relatively expensive valuation (high P/E, low yield). These are partially offset by a conservative balance sheet and strong technical momentum with the stock trading well above key moving averages.

Positive Factors

Recent Revenue GrowthThe return to strong revenue growth shows renewed demand or execution across the company’s formulation business. If sustained, higher sales can improve operating scale, support reinvestment, and strengthen the company’s ability to build earnings over the next several quarters.

Negative Factors

Persistent Negative Cash FlowSustained negative operating and free cash flow indicates that reported profits are not converting into liquidity. The resulting funding needs can constrain investment, increase reliance on financing or working-capital management, and weaken financial flexibility if the pattern persists.

Medicamen Biotech Limited (MEDICAMEQ) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 4.32B
Dividend Yield: 0.39%
Average Volume (3M): 3,809
Price to Earnings (P/E): 32.0
Beta (1Y): 1.07
Revenue Growth: 24.66%
EPS Growth: 10.89%
Country: India
Employees: 405
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Medicamen Biotech Limited Business Overview & Revenue Model

Company Description

Medicamen Biotech Limited, established in 1993 and headquartered in New Delhi, India, is an Indian pharmaceutical firm primarily engaged in the manufacturing and distribution of a diverse range of medicinal formulations. Its product line encompasses...

Medicamen Biotech Limited Financial Statement Overview

Summary

Mixed fundamentals. Balance sheet is a clear strength (moderate leverage with expanding equity), but operating performance has been uneven and cash generation is the key concern: operating and free cash flow have been negative for multiple years, including a sharp deterioration in FY2026. Income statement shows improved revenue growth recently, but profitability has weakened versus earlier years.

Income Statement

62Positive

Balance Sheet

78Positive

Cash Flow

25Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	2.03B	1.98B	1.63B	1.79B	1.41B	1.15B
Gross Profit	593.22M	540.86M	389.90M	852.01M	687.74M	479.88M
EBITDA	214.06M	227.00M	201.02M	245.66M	239.99M	258.07M
Net Income	108.29M	96.41M	71.08M	109.31M	148.44M	148.98M
Balance Sheet
Total Assets	0	3.72B	2.97B	2.95B	2.79B	2.26B
Cash, Cash Equivalents and Short-Term Investments	312.64M	312.64M	37.59M	147.86M	207.79M	38.25M
Total Debt	0	477.84M	332.53M	311.12M	257.09M	257.96M
Total Liabilities	-2.76B	964.38M	841.04M	875.67M	851.03M	792.24M
Stockholders Equity	2.76B	2.76B	2.13B	2.07B	1.93B	1.46B
Cash Flow
Free Cash Flow	-145.81M	-397.08M	-119.32M	-130.31M	-128.94M	-44.99M
Operating Cash Flow	-124.06M	-349.31M	-98.59M	-67.44M	-62.93M	41.09M
Investing Cash Flow	-15.21M	-47.78M	-23.78M	-55.63M	-58.80M	-84.73M
Financing Cash Flow	538.49M	672.13M	12.16M	63.13M	291.27M	42.98M

Medicamen Biotech Limited Technical Analysis

Technical Analysis SentimentNegative

Last Price255.50

Price Trends

50DMA286.96Negative

100DMA262.52Negative

200DMA278.21Negative

Market Momentum

MACD-11.11Positive

RSI37.85Neutral

STOCH19.78Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MEDICAMEQ, the sentiment is Negative. The current price of 255.50 is below the 20-day moving average (MA) of 286.02, below the 50-day MA of 286.96, and below the 200-day MA of 278.21, indicating a bearish trend. The MACD of -11.11 indicates Positive momentum. The RSI at 37.85 is Neutral, neither overbought nor oversold. The STOCH value of 19.78 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:MEDICAMEQ.

Medicamen Biotech Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:MEDICAMEQ against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:MEDICAMEQ	60Neutral	INR 3.47B	31.98	―	0.39%	24.66%	10.89%
IN:VALIANTLAB	59Neutral	INR 6.95B	43.52	―	―	89.64%	10627.64%
IN:BAFNAPH	58Neutral	INR 10.60B	136.14	―	―	-3.14%	-5.80%
IN:MEDICO	58Neutral	INR 1.55B	11.14	―	―	49.96%	33.70%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:ALBERTDAVD	54Neutral	INR 4.35B	19.29	―	0.65%	11.43%	258.53%
IN:NECLIFE	44Neutral	INR 2.00B	-0.90	―	―	-99.53%	-41.93%

* General Sector Average

Performance Comparison

IN:MEDICAMEQ and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:MEDICAMEQ	Medicamen Biotech Limited	255.50	-120.56	-32.06%
IN:ALBERTDAVD	Albert David Ltd	762.90	-114.67	-13.07%
IN:BAFNAPH	Bafna Pharmaceuticals Limited	447.90	285.75	176.23%
IN:MEDICO	Medico Remedies Ltd.	18.65	-31.30	-62.66%
IN:NECLIFE	Nectar Lifesciences Ltd.	10.29	-4.61	-30.94%
IN:VALIANTLAB	Valiant Laboratories Ltd.	127.90	44.90	54.10%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 16, 2026

Medicamen Biotech Limited AI Stock Analysis